This is the point I have made over some time: there is no evidence whatsoever that BIT225 has any effect in treatment non-responders, and no particular reason to suspect that it would. To prove it either way will require a new series of trials, sufficiently expensive to absolutely require support from a larger company, and given that current or nearly available treatments give 97-98% cure, is a market of 2-3% of first world HCV actually large enough to be commercially viable. Back in 2012 I asked this company about what their reaction was to sofosbuvir, and got the response "the market is big enough for other drugs", followed by 4 years of further trials with PEG-riba when that combination was clearly dead in the water. This company has been way too slow on its feet.
BIT Price at posting:
6.5¢ Sentiment: Sell Disclosure: Not Held
